v3.26.1
Summary of Significant Accounting Policies - Schedule of Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Total operating expenses $ 21,181 $ 17,964
Loss from operations (21,181) (17,964)
Other income, net 1,118 1,409
Change in fair value of warrant liabilities (18,962) 10,060
Net loss (39,025) (6,495)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Tegoprubart - kidney transplantation programs 5,414 8,531
Tegoprubart - other development programs 0 (168)
Manufacturing 7,786 1,670
Personnel-related expenses 3,803 3,448
Stock-based compensation 2,202 2,864
Other segment items 1,976 1,619
Total operating expenses 21,181 17,964
Loss from operations (21,181) (17,964)
Other income, net 1,118 1,409
Change in fair value of warrant liabilities (18,962) 10,060
Net loss $ (39,025) $ (6,495)